MCID: OVR011
MIFTS: 28

Ovarian Mucinous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Mucinous Adenocarcinoma

MalaCards integrated aliases for Ovarian Mucinous Adenocarcinoma:

Name: Ovarian Mucinous Adenocarcinoma 12 14 69
Mucinous Carcinoma of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3606
NCIt 47 C5243
UMLS 69 C1335167

Summaries for Ovarian Mucinous Adenocarcinoma

MalaCards based summary : Ovarian Mucinous Adenocarcinoma, also known as mucinous carcinoma of ovary, is related to mucinous adenocarcinoma and mucinous adenocarcinoma of ovary. An important gene associated with Ovarian Mucinous Adenocarcinoma is CDX2 (Caudal Type Homeobox 2). The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and bone, and related phenotype is Decreased Hepatitis C virus replication.

Related Diseases for Ovarian Mucinous Adenocarcinoma

Diseases related to Ovarian Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
id Related Disease Score Top Affiliating Genes
1 mucinous adenocarcinoma 30.8 AMACR KRT20
2 mucinous adenocarcinoma of ovary 11.0
3 stromal predominant kidney wilms' tumor 10.4 AMACR CDX2
4 sensory system cancer 10.4 CDX2 KRT20
5 lung occult small cell carcinoma 10.4 CDX2 KRT20
6 fibroepithelial polyp of urethra 10.4 CDX2 KRT20
7 chronic neutrophilic leukemia 10.4 CDX2 KRT20
8 gastric adenocarcinoma 10.4 CDX2 KRT20
9 childhood teratoma of the ovary 10.4 CDX2 KRT20
10 intrahepatic cholangiocarcinoma 10.4 CDX2 KRT20
11 giant cell tumor 10.4 CDX2 KRT20
12 ovarian melanoma 10.4 CDX2 KRT20
13 fibroma 10.3 CDX2 KRT20
14 mesenchymoma 10.3 CDX2 KRT20
15 wissler's syndrome 10.3 CDX2 KRT20
16 human t-cell leukemia virus type 1 10.3 CDX2 KRT20
17 spastic ataxia 3 10.3 CDX2 KRT20
18 pituitary carcinoma 10.3 AMACR UPK3A
19 glycogen-rich clear cell breast carcinoma 10.3 AMACR UPK3A
20 bile duct clear cell adenocarcinoma 10.3 CDX2 MUC2
21 breast adenomyoepithelial adenosis 10.3 AMACR UPK3A
22 postpoliomyelitis syndrome 10.3 CDX2 KRT20
23 fibular collateral ligament bursitis 10.3 AMACR UPK3A
24 vulva squamous cell carcinoma 10.3 KRT20 UPK3A
25 tubular adenocarcinoma 10.3 CDX2 MUC2
26 cholangitis 10.3 CDX2 MUC2
27 pyloric antrum cancer 10.2 CDX2 MUC2
28 breast secretory carcinoma 10.2 KRT20 UPK3A
29 adenocarcinoma 10.2
30 intracranial sinus thrombosis 10.2 CDX2 MUC2
31 advanced sleep phase syndrome 10.2 CDX2 MUC2
32 classic variant of chromophobe renal cell carcinoma 10.2 CDX2 MUC2
33 malignant biphasic mesothelioma 10.2 AMACR MUC2
34 hip subluxation 10.2 CDX2 MUC2
35 ascending colon cancer 10.2 KRT20 MUC2
36 sohval soffer syndrome 10.2 CDX2 MUC2
37 paralytic ileus 10.2 CDX2 KRT20
38 ureter adenocarcinoma 10.2 CDX2 MUC2
39 testicular trophoblastic tumor 10.2 KRT20 MUC2
40 pericholangitis 10.2 CDX2 MUC2
41 sarcomatoid renal cell carcinoma 10.2 AMACR KRT20
42 fallopian tube mucinous tumor 10.2 CDX2 KRT20
43 gastrointestinal neuroendocrine tumor 10.1 CDX2 MUC2
44 perivascular epithelioid cell tumor 10.1 KRT20 UPK3A
45 central nervous system disease 10.1 CDX2 KRT20
46 uterine corpus apoplectic leiomyoma 10.1 KRT20 MUC2
47 splenic infarction 10.1 AMACR UPK3A
48 striated muscle rhabdoid tumor 10.0 KRT20 MUC2
49 choriocarcinoma 10.0 KRT20 MUC2
50 prostate transitional cell carcinoma 10.0 KRT20 UPK3A

Graphical network of the top 20 diseases related to Ovarian Mucinous Adenocarcinoma:



Diseases related to Ovarian Mucinous Adenocarcinoma

Symptoms & Phenotypes for Ovarian Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Hepatitis C virus replication GR00180-A-1 8.92 NOM1 UPK3A
2 Decreased Hepatitis C virus replication GR00180-A-2 8.92 NOM1 UPK3A

Drugs & Therapeutics for Ovarian Mucinous Adenocarcinoma

Drugs for Ovarian Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Doxorubicin Approved, Investigational Phase 2, Phase 3, Phase 1 23214-92-8 31703
6
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
9
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
10
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
11
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
12
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
13
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
14
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
15
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
16
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Doxil Approved June 1999 Phase 2, Phase 3, Phase 1 31703
19
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
20
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
21
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
26 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
27 Antibodies Phase 3,Phase 2,Phase 1
28 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
29 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
30 Immunoglobulins Phase 3,Phase 2,Phase 1
31 Mitogens Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 2, Phase 3, Phase 1
33 Antibiotics, Antitubercular Phase 2, Phase 3, Phase 1
34 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
35 topoisomerase I inhibitors Phase 2, Phase 3, Phase 1
36 Topoisomerase Inhibitors Phase 2, Phase 3, Phase 1
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
39 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
40 Alkylating Agents Phase 3,Phase 2,Phase 1
41 Antirheumatic Agents Phase 3,Phase 2,Phase 1
42 Carotenoids Phase 3
43 Micronutrients Phase 3
44 Trace Elements Phase 3
45 Anticoagulants Phase 2, Phase 3
46 Antineoplastic Agents, Hormonal Phase 2, Phase 3
47 Aromatase Inhibitors Phase 2, Phase 3
48 Bone Density Conservation Agents Phase 2, Phase 3
49 Calcium, Dietary Phase 2, Phase 3
50 Chelating Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 92)

id Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
8 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
9 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
10 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
11 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
12 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
13 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
14 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
15 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
16 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
17 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
18 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
19 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
20 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
21 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
22 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
23 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
24 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
25 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
26 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
27 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
28 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
29 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
30 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
31 Randomized Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer Completed NCT00993655 Phase 2 carboplatin;cisplatin;paclitaxel
32 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2 ABT-888;Cyclophosphamide
33 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
34 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2 Cyclophosphamide
35 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
36 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
37 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
38 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 paclitaxel;carboplatin;docetaxel;metformin hydrochloride;placebo
39 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Recruiting NCT02953457 Phase 1, Phase 2 Olaparib
40 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02627443 Phase 1, Phase 2 ATR Kinase Inhibitor VX-970;Carboplatin;Gemcitabine Hydrochloride
41 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
42 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
43 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
44 Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 selumetinib
45 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2 Everolimus;Letrozole
46 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
47 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2 Dasatinib
48 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
49 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
50 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride

Search NIH Clinical Center for Ovarian Mucinous Adenocarcinoma

Genetic Tests for Ovarian Mucinous Adenocarcinoma

Anatomical Context for Ovarian Mucinous Adenocarcinoma

MalaCards organs/tissues related to Ovarian Mucinous Adenocarcinoma:

39
Ovary, Liver, Bone, Endothelial, Brain, Bone Marrow

Publications for Ovarian Mucinous Adenocarcinoma

Articles related to Ovarian Mucinous Adenocarcinoma:

id Title Authors Year
1
Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma. ( 27060927 )
2016
2
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions. ( 26576867 )
2015
3
Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis. ( 25197383 )
2014
4
Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases. ( 24487473 )
2014
5
A case of ovarian mucinous adenocarcinoma in a premenarcheal girl. ( 22016113 )
2012
6
Prognostic significance of stromal microinvasion in the intestinal type of ovarian mucinous adenocarcinoma. ( 21556953 )
2011
7
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. ( 19926591 )
2010
8
Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. ( 15721446 )
2005
9
An ovarian mucinous adenocarcinoma arising from mature cystic teratoma associated with respiratory type tissue: a case report. ( 15656343 )
2004
10
Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin. ( 9158713 )
1997

Variations for Ovarian Mucinous Adenocarcinoma

Cosmic variations for Ovarian Mucinous Adenocarcinoma:

9 (show top 50) (show all 134)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 4
2 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 4
3 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 4
4 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 4
5 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 4
6 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 4
7 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 4
8 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 4
9 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 4
10 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 4
11 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 4
12 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 4
13 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 4
14 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 4
15 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 4
16 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 4
17 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 4
18 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 4
19 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 4
20 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 4
21 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 4
22 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 4
23 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 4
24 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 4
25 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 4
26 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 4
27 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 4
28 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 4
29 COSM20640 WEE2 ovary,NS,carcinoma,mucinous carcinoma c.1193G>A p.R398H 3
30 COSM20669 ULK1 ovary,NS,carcinoma,mucinous carcinoma c.868G>A p.V290M 3
31 COSM20712 TRRAP ovary,NS,carcinoma,mucinous carcinoma c.5786G>T p.R1929L 3
32 COSM43899 TP53 ovary,NS,carcinoma,mucinous carcinoma c.434T>C p.L145P 3
33 COSM10656 TP53 ovary,NS,carcinoma,mucinous carcinoma c.742C>T p.R248W 3
34 COSM10801 TP53 ovary,NS,carcinoma,mucinous carcinoma c.404G>A p.C135Y 3
35 COSM10660 TP53 ovary,NS,carcinoma,mucinous carcinoma c.818G>A p.R273H 3
36 COSM10648 TP53 ovary,NS,carcinoma,mucinous carcinoma c.524G>A p.R175H 3
37 COSM43751 TP53 ovary,NS,carcinoma,mucinous carcinoma c.673-1G>A p.? 3
38 COSM10733 TP53 ovary,NS,carcinoma,mucinous carcinoma c.574C>T p.Q192* 3
39 COSM10731 TP53 ovary,NS,carcinoma,mucinous carcinoma c.707A>G p.Y236C 3
40 COSM11089 TP53 ovary,NS,carcinoma,mucinous carcinoma c.584T>C p.I195T 3
41 COSM44827 TP53 ovary,NS,carcinoma,mucinous carcinoma c.358A>G p.K120E 3
42 COSM10704 TP53 ovary,NS,carcinoma,mucinous carcinoma c.844C>T p.R282W 3
43 COSM10645 TP53 ovary,NS,carcinoma,mucinous carcinoma c.527G>T p.C176F 3
44 COSM6932 TP53 ovary,NS,carcinoma,mucinous carcinoma c.733G>A p.G245S 3
45 COSM46470 TP53 ovary,NS,carcinoma,mucinous carcinoma c.922C>G p.L308V 3
46 COSM10891 TP53 ovary,NS,carcinoma,mucinous carcinoma c.814G>A p.V272M 3
47 COSM43568 TP53 ovary,NS,carcinoma,mucinous carcinoma c.772G>T p.E258* 3
48 COSM10662 TP53 ovary,NS,carcinoma,mucinous carcinoma c.743G>A p.R248Q 3
49 COSM10768 TP53 ovary,NS,carcinoma,mucinous carcinoma c.535C>T p.H179Y 3
50 COSM11205 TP53 ovary,NS,carcinoma,mucinous carcinoma c.796G>C p.G266R 3

Expression for Ovarian Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Ovarian Mucinous Adenocarcinoma.

Pathways for Ovarian Mucinous Adenocarcinoma

GO Terms for Ovarian Mucinous Adenocarcinoma

Sources for Ovarian Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....